The study builds on data from an early-stage study which evaluated CD19 CAR-NK cell therapy in combination with the Rituximab ...

Early results from the ongoing QUILT-106 clinical trial (NCT06334991) show that the treatment combination of CD19 chimeric antigen receptor natural killer (CAR-NK) cells with rituximab (Rituxan) can ...

Patients with Waldenström Non-Hodgkin lymphoma in the U.S. achieved durable complete responses of up to 15 months using a chemotherapy-free CD19 CAR-NK (chimeric antigen receptor natural killer) cell ...

A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.

First Phase 2 chemotherapy-free, lymphodepletion-free, off-the-shelf CAR-NK cell therapy plus ANKTIVA® and rituximab regimen ...

Two patients with Waldenstrom’s NHL achieved complete remission with CAR NK cell therapy and rituximab, maintaining remission for 7 and 15 months without further treatment. The therapy is chemotherapy ...

CD19 CAR NK cell therapy, alone or with rituximab, shows promise in relapsed/refractory B-cell NHL, including Waldenström macroglobulinemia. Two heavily pretreated WM patients achieved complete ...

Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s Non-Hodgkins lymphoma (NHL). Long-term evaluable patients demonstrate ongoing ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

Phase 1/2 clinical study of NY-ESO-1 TCR/IL-15 NK for relapsed or refractory multiple myeloma commences on track NY-ESO-1 TCR/IL-15 NK is the lead clinical program of Syena, a Replay and MD Anderson ...